{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:44:36Z","timestamp":1747151076931,"version":"3.40.5"},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>It is unknown whether there are differences in efficacy and safety between quetiapine extended\u2010release, 300\u00a0mg\/d (QUEXR300), and olanzapine, 5\u201020\u00a0mg\/d (OLA), for Japanese patients with bipolar depression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery\u2010\u00c5sberg Depression Rating Scale and 17\u2010item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR\u00a0=\u00a05.517; 95% CrI\u00a0=\u00a01.563, 19.787), while OLA was associated with greater increase body weight (SMD\u00a0=\u00a0\u22120.488; 95% CrI\u00a0=\u00a0\u22120.881, \u22120.089) and blood prolactin levels (SMD\u00a0=\u00a0\u22120.642; 95% CrI\u00a0=\u00a0\u22121.073, \u22120.213) than QUEXR300, and a greater decrease in high\u2010density lipoprotein cholesterol levels (SMD\u00a0=\u00a0\u22120.408; 95% CrI\u00a0=\u00a0\u22120.785, \u22120.030) than QUEXR300.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although the two drugs\u2019 efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long\u2010term, head\u2010to\u2010head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.<\/jats:p><\/jats:sec>","DOI":"10.1002\/npr2.12070","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T18:04:32Z","timestamp":1562609072000},"page":"256-259","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quetiapine extended\u2010release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-2236","authenticated-orcid":false,"given":"Taro","family":"Kishi","sequence":"first","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Ikuta","sequence":"additional","affiliation":[{"name":"Department of Communication Sciences and Disorders, Digital Neuroscience Laboratory The University of Mississippi University Park Mississippi USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Jikei University School of Medicine Minato\u2010ku Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Fujita Health University School of Medicine Toyoake Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"PMDA.Pharmaceuticals and Medical Devices Agency.https:\/\/wwwpmdagojp\/english\/indexhtml."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.108357"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-138"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-4977-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2019.05.020"},{"key":"e_1_2_9_11_1","unstructured":"HigginsJ CochraneGS.Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration 2011.www.cochrane-handbook.org."}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnpr2.12070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.12070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T17:32:54Z","timestamp":1693848774000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/npr2.12070"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12070","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"type":"print","value":"2574-173X"},{"type":"electronic","value":"2574-173X"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"2019-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}